CAS
128270-60-0
AA-Sequence
D-Phe-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu
Originator
Biogen Idec
First marketed by
The Medicines Company UK Ltd.
Name of FDF
Angiox®, Angiomax®
Original FDF
Powder for reconstitution and IV injection
Other FDF
RTU solution
Mode of Action
Thrombin inhibitor. It inhibits both circulating and clot-bound thrombin, while also inhibiting thrombin-mediated platelet activation and aggregation (Cardiovascular)
Indications
Treatment of heparin-induced thrombocytopenia and for the prevention of thrombosis.
Patent status
Generic products are available, a RTU formulation is still patented until 2029-08-20